The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
While momentum can be a leading indicator, it has burned many investors as it doesn’t always correlate with long-term success. Keeping that in mind, here are two stocks with the fundamentals to back up their performance and one not so much.
One Stock to Sell:
EchoStar (SATS)
One-Month Return: +4%
Following its 2023 acquisition of DISH Network, EchoStar (NASDAQ: SATS) provides satellite communications, pay-TV services, wireless networks, and broadband solutions across consumer and enterprise markets.
Why Do We Steer Clear of SATS?
- Sales tumbled by 6.1% annually over the last two years, showing market trends are working against its favor during this cycle
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
- Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes
EchoStar is trading at $136.69 per share, or 29.5x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why SATS doesn’t pass our bar.
Two Stocks to Watch:
Vita Coco (COCO)
One-Month Return: +52.8%
Founded in 2004 followed by a 2021 IPO, The Vita Coco Company (NASDAQ: COCO) offers coconut water products that are a natural way to quench thirst.
Why Do We Love COCO?
- Unit sales were phenomenal over the past two years, showing demand is robust and retailers can’t stock enough of its products
- Earnings growth has trumped its peers over the last three years as its EPS has compounded at 52.4% annually
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures, and its rising returns show it’s making even more lucrative bets
At $76.09 per share, Vita Coco trades at 41.2x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Astrana Health (ASTH)
One-Month Return: +34%
Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.
Why Are We Fans of ASTH?
- Annual revenue growth of 55.7% over the last two years was superb and indicates its market share increased during this cycle
- Forecasted revenue growth of 16.7% for the next 12 months indicates its momentum over the last two years is sustainable
- Earnings per share grew by 13.2% annually over the last five years and trumped its peers
Astrana Health’s stock price of $39.16 implies a valuation ratio of 13.2x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
